Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
MADCAM1 Biologics Sequence Review Report 2026: Mucosal addressin cell adhesion molecule 1 Similarity and Patent-Risk Signals
8 min read
MADCAM1 Biologics Sequence Review Report 2026: Mucosal addressin cell adhesion molecule 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of MADCAM1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRIG3 Biologics Sequence Review Report 2026: Leucine-rich repeats and immunoglobulin-like domains protein 3 Similarity and Patent-Risk Signals
8 min read
LRIG3 Biologics Sequence Review Report 2026: Leucine-rich repeats and immunoglobulin-like domains protein 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LRIG3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRIG2 Biologics Sequence Review Report 2026: Leucine-rich repeats and immunoglobulin-like domains protein 2 Similarity and Patent-Risk Signals
8 min read
LRIG2 Biologics Sequence Review Report 2026: Leucine-rich repeats and immunoglobulin-like domains protein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LRIG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRIG1 Biologics Sequence Review Report 2026: Leucine-rich repeats and immunoglobulin-like domains protein 1 Similarity and Patent-Risk Signals
8 min read
LRIG1 Biologics Sequence Review Report 2026: Leucine-rich repeats and immunoglobulin-like domains protein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LRIG1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LAMP3 Biologics Sequence Review Report 2026: Lysosome-associated membrane glycoprotein 3 Similarity and Patent-Risk Signals
8 min read
LAMP3 Biologics Sequence Review Report 2026: Lysosome-associated membrane glycoprotein 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LAMP3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LAMP2 Biologics Sequence Review Report 2026: Lysosome-associated membrane glycoprotein 2 Similarity and Patent-Risk Signals
8 min read
LAMP2 Biologics Sequence Review Report 2026: Lysosome-associated membrane glycoprotein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LAMP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LAMP1 Biologics Sequence Review Report 2026: Lysosome-associated membrane glycoprotein 1 Similarity and Patent-Risk Signals
8 min read
LAMP1 Biologics Sequence Review Report 2026: Lysosome-associated membrane glycoprotein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LAMP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KLRC4 Biologics Sequence Review Report 2026: NKG2-F type II integral membrane protein Similarity and Patent-Risk Signals
8 min read
KLRC4 Biologics Sequence Review Report 2026: NKG2-F type II integral membrane protein Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of KLRC4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KISS1R Biologics Sequence Review Report 2026: KiSS-1 receptor Similarity and Patent-Risk Signals
8 min read
KISS1R Biologics Sequence Review Report 2026: KiSS-1 receptor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of KISS1R sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAG2 Biologics Sequence Review Report 2026: Protein jagged-2 Similarity and Patent-Risk Signals
8 min read
JAG2 Biologics Sequence Review Report 2026: Protein jagged-2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of JAG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAG1 Biologics Sequence Review Report 2026: Protein jagged-1 Similarity and Patent-Risk Signals
8 min read
JAG1 Biologics Sequence Review Report 2026: Protein jagged-1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of JAG1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITGB4 Biologics Sequence Review Report 2026: Integrin beta-4 Similarity and Patent-Risk Signals
8 min read
ITGB4 Biologics Sequence Review Report 2026: Integrin beta-4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of ITGB4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →